Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/27/21
Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both IndicationsGlobeNewsWire • 02/18/21
Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate UpdateGlobeNewsWire • 02/17/21
Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland ConferenceGlobeNewsWire • 02/15/21
Alimera Sciences, Inc. Discusses Its 2021 Global Expansion Strategy with The Stock Day PodcastNewsfile Corp • 02/01/21
Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020GlobeNewsWire • 01/19/21
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual ConferenceGlobeNewsWire • 01/05/21
Alimera Sciences to Present at the 13th Annual LD Micro Main Event Virtual ConferenceGlobeNewsWire • 12/08/20
Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020GlobeNewsWire • 11/16/20
Alimera Sciences Announces Real-World Clinical Data for ILUVIEN® to be Presented at the American Academy of Ophthalmology 2020 Virtual ConferenceGlobeNewsWire • 11/12/20
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/31/20
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate UpdateGlobeNewsWire • 10/22/20
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual CongressGlobeNewsWire • 09/23/20
UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020GlobeNewsWire • 09/09/20
Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020GlobeNewsWire • 09/09/20
Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular EdemaGlobeNewsWire • 09/01/20
Alimera Sciences Announces National Reimbursement Granted for ILUVIEN® in the NetherlandsGlobeNewsWire • 08/26/20
Alimera Sciences to Present at the LD Micro 500 Virtual Conference on September 2, 2020GlobeNewsWire • 08/25/20
Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic CountriesGlobeNewsWire • 08/13/20